{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T00:16:00Z","timestamp":1714004160208},"reference-count":32,"publisher":"Bentham Science Publishers Ltd.","issue":"4","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMM"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>The coronavirus disease 2019 (Covid-19) pandemic has been considered a\nmajor threat to human health. Effective therapeutic approaches are urgently required.\nSpike protein and the Angiotensin-converting enzyme 2 (ACE2) receptors have critical\nroles in SARS-CoV-2 infection. As a result, these two proteins are considered potential\ntargets for the development of a wide variety of biotherapeutics and vaccines for\ncontrolling Covid-19. The fusion proteins have desirable medicinal properties, including\nhigh serum half-life, stability, and solubility in the body. Moreover, other Fc-fusion\nproteins used to treat other diseases have no known side effects. These Fc-fusion\nproteins are valuable biopharmaceuticals and have been proposed as therapeutic\ncandidates for the treatment and prevention of Covid-19 owing to their potential\ntherapeutic benefits.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1566524023666230410093243","type":"journal-article","created":{"date-parts":[[2023,4,11]],"date-time":"2023-04-11T04:24:15Z","timestamp":1681187055000},"page":"428-434","update-policy":"http:\/\/dx.doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Covid-19 Prevention and Treatment by Targeting Fc-fusion\nProteins: An Experience to Fight Emerging Diseases"],"prefix":"10.2174","volume":"24","author":[{"given":"Hamed","family":"Zare","sequence":"first","affiliation":[{"name":"Recombinant Proteins Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR,\nTehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tahereh","family":"Farkhondeh","sequence":"additional","affiliation":[{"name":"Department of Toxicology and Pharmacology, School of Pharmacy, Birjand University of\nMedical Sciences, Birjand, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamid","family":"Bakherad","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Biotechnology and Isfahan Pharmaceutical\nSciences Research Center, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical\nSciences, Isfahan, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hengame","family":"Sharifi","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, School of Medicine, Birjand University of\nMedical Sciences, Birjand, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryam","family":"Hosseinzade Shirzeyli","sequence":"additional","affiliation":[{"name":"Department of Anatomical Sciences, School of Medicine, Shahid Beheshti\nUniversity of Medical Sciences, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saeed","family":"Samarghandian","sequence":"additional","affiliation":[{"name":"Healthy Ageing Research Centre, Neyshabur University of\nMedical Sciences, Neyshabur. Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fahimeh","family":"Ghasemi","sequence":"additional","affiliation":[{"name":"Cellular and Molecular Research Center, Birjand University of Medical\nSciences, Birjand, Iran"},{"name":"Department of Medical Biotechnology, School of Medicine, Birjand University of\nMedical Sciences, Birjand, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"682953","DOI":"10.3389\/fpls.2021.682953","volume":"12","author":"Siriwattananon K.","year":"2021","unstructured":"Siriwattananon K.; Manopwisedjaroen S.; Shanmugaraj B.; Plant-produced receptor-binding domain of SARS-CoV-2 elicits potent neutralizing responses in mice and non-human primates. Front Plant Sci  2021,12,682953","journal-title":"Front Plant Sci"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"e068373","DOI":"10.1136\/bmj-2021-068373","volume":"376","author":"Li X.","year":"2022","unstructured":"Li X.; Ravent\u00f3s B.; Roel E.; Association between covid-19 vaccination, SARS-CoV-2 infection, and risk of immune mediated neurological events: population based cohort and self-controlled case series analysis. BMJ  2022,376,e068373","journal-title":"BMJ"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s11684-021-0913-y","volume":"16","author":"Shao Y.","year":"2022","unstructured":"Shao Y.; Wu Y.; Feng Y.; Xu W.; Xiong F.; Zhang X.; SARS-CoV-2 vaccine research and immunization strategies for improved control of the COVID-19 pandemic. Front Med  2022,16(2),185-195","journal-title":"Front Med"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/j.cell.2020.03.045","volume":"181","author":"Wang Q.","year":"2020","unstructured":"Wang Q.; Zhang Y.; Wu L.; Structural and functional basis of SARS-CoV-2 entry by using human ACE2. Cell  2020,181(4),894-904.e9","journal-title":"Cell"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"112868","DOI":"10.1016\/j.bios.2020.112868","volume":"175","author":"Kim H.Y.","year":"2021","unstructured":"Kim H.Y.; Lee J.H.; Kim M.J.; Development of a SARS-CoV-2-specific biosensor for antigen detection using scFv-Fc fusion proteins. Biosens Bioelectron  2021,175,112868","journal-title":"Biosens Bioelectron"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"2000566","DOI":"10.1002\/biot.202000566","volume":"16","author":"Castilho A.","year":"2021","unstructured":"Castilho A.; Schwestka J.; Kienzl N.F.; Generation of enzymatically competent SARS\u2010CoV\u20102 decoy receptor ACE2\u2010Fc in glycoengineered Nicotiana benthamiana. Biotechnol J  2021,16(6),2000566","journal-title":"Biotechnol J"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1021\/acscentsci.1c00120","volume":"7","author":"Li Y.","year":"2021","unstructured":"Li Y.; Tenchov R.; Smoot J.; Liu C.; Watkins S.; Zhou Q.; A comprehensive review of the global efforts on COVID-19 vaccine development. ACS Cent Sci  2021,7(4),512-533","journal-title":"ACS Cent Sci"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"123519","DOI":"10.1016\/j.talanta.2022.123519","volume":"246","author":"Camperi J.","year":"2022","unstructured":"Camperi J.; Dahotre S.; Guillarme D.; Monitoring multiple quality attributes of a complex Fc-fusion protein during cell culture production processes by mD-LC-MS peptide mapping. Talanta  2022,246,123519","journal-title":"Talanta"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"5653","DOI":"10.1016\/j.vaccine.2020.06.066","volume":"38","author":"Ren W.","year":"2020","unstructured":"Ren W.; Sun H.; Gao G.F.; Recombinant SARS-CoV-2 spike S1-Fc fusion protein induced high levels of neutralizing responses in nonhuman primates. Vaccine  2020,38(35),5653-5658","journal-title":"Vaccine"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s40259-015-0133-6","volume":"29","author":"Strohl W.R.","year":"2015","unstructured":"Strohl W.R.; Fusion proteins for half-life extension of biologics as a strategy to make biobetters. BioDrugs  2015,29(4),215-239","journal-title":"BioDrugs"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1002\/jps.23984","volume":"103","author":"Wu B.","year":"2014","unstructured":"Wu B.; Sun Y.N.; Pharmacokinetics of Peptide\u2013Fc Fusion Proteins. J Pharm Sci  2014,103(6),1928","journal-title":"J Pharm Sci"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.tibtech.2014.11.001","volume":"33","author":"Levin D.","year":"2015","unstructured":"Levin D.; Golding B.; Strome S.E.; Sauna Z.E.; Fc fusion as a platform technology: potential for modulating immunogenicity. Trends Biotechnol  2015,33(1),27-34","journal-title":"Trends Biotechnol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/jssc.202000765","volume":"44","author":"Duivelshof B.L.","year":"2021","unstructured":"Duivelshof B.L.; Murisier A.; Camperi J.; Therapeutic Fc\u2010fusion proteins: Current analytical strategies. J Sep Sci  2021,44(1),35-62","journal-title":"J Sep Sci"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1002\/emmm.201201379","volume":"4","author":"Czajkowsky D.M.","year":"2012","unstructured":"Czajkowsky D.M.; Hu J.; Shao Z.H.; Pleass R.J.; Fc\u2010fusion proteins: New developments and future perspectives. EMBO Mol Med  2012,4(10),1015-1028","journal-title":"EMBO Mol Med"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.3389\/fimmu.2017.01860","volume":"8","author":"Yang C.","year":"2018","unstructured":"Yang C.; Gao X.; Gong R.; Engineering of Fc fragments with optimized physicochemical properties implying improvement of clinical potentials for Fc-based therapeutics. Front Immunol  2018,8,1860","journal-title":"Front Immunol"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"2977","DOI":"10.1007\/s00705-014-2163-7","volume":"159","author":"Oh J.","year":"2014","unstructured":"Oh J.; Lee K.W.; Choi H.W.; Lee C.; Immunogenicity and protective efficacy of recombinant S1 domain of the porcine epidemic diarrhea virus spike protein. Arch Virol  2014,159(11),2977-2987","journal-title":"Arch Virol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"e0237295","DOI":"10.1371\/journal.pone.0237295","volume":"15","author":"Bernardi A.","year":"2020","unstructured":"Bernardi A.; Huang Y.; Harris B.; Development and simulation of fully glycosylated molecular models of ACE2-Fc fusion proteins and their interaction with the SARS-CoV-2 spike protein binding domain. PLoS One  2020,15(8),e0237295","journal-title":"PLoS One"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1016\/j.ijbiomac.2020.10.1205","volume":"165","author":"Liu P","year":"2020","unstructured":"Liu P; Xie X; Gao L; Jin J.; Designed variants of ACE2-Fc that decouple anti-SARS-CoV-2 activities from unwanted cardiovascular effects. Int J Biol Macromol  2020,165(Pt B),1626-33","journal-title":"Int J Biol Macromol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"e12828","DOI":"10.15252\/emmm.202012828","volume":"13","author":"Huang K.Y.","year":"2021","unstructured":"Huang K.Y.; Lin M.S.; Kuo T.C.; Humanized COVID\u201019 decoy antibody effectively blocks viral entry and prevents SARS\u2010CoV\u20102 infection. EMBO Mol Med  2021,13(1),e12828","journal-title":"EMBO Mol Med"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1186\/s13054-017-1823-x","volume":"21","author":"Khan A.","year":"2017","unstructured":"Khan A.; Benthin C.; Zeno B.; A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome. Crit Care  2017,21(1),234","journal-title":"Crit Care"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"1702638","DOI":"10.1183\/13993003.02638-2017","volume":"51","author":"Hemnes A.R.","year":"2018","unstructured":"Hemnes A.R.; Rathinasabapathy A.; Austin E.A.; A potential therapeutic role for angiotensin-converting enzyme 2 in human pulmonary arterial hypertension. Eur Respir J  2018,51(6),1702638","journal-title":"Eur Respir J"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.kint.2018.01.029","volume":"94","author":"Liu P.","year":"2018","unstructured":"Liu P.; Wysocki J.; Souma T.; Novel ACE2-Fc chimeric fusion provides long-lasting hypertension control and organ protection in mouse models of systemic renin angiotensin system activation. Kidney Int  2018,94(1),114-125","journal-title":"Kidney Int"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"108528","DOI":"10.1016\/j.celrep.2020.108528","volume":"33","author":"Tada T.","year":"2020","unstructured":"Tada T.; Fan C.; Chen J.S.; An ACE2 microbody containing a single immunoglobulin Fc domain is a potent inhibitor of SARS-CoV-2. Cell Rep  2020,33(12),108528","journal-title":"Cell Rep"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.omtm.2021.05.004","volume":"21","author":"Zhang X.","year":"2021","unstructured":"Zhang X.; Han P.; Wang H.; Engineering mesenchymal stromal cells with neutralizing and anti-inflammatory capability against SARS-CoV-2 infection. Mol Ther Methods Clin Dev  2021,21,754-764","journal-title":"Mol Ther Methods Clin Dev"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"604663","DOI":"10.3389\/fpls.2020.604663","volume":"11","author":"Siriwattananon K.","year":"2021","unstructured":"Siriwattananon K.; Manopwisedjaroen S.; Kanjanasirirat P.; Development of plant-produced recombinant ACE2-Fc fusion protein as a potential therapeutic agent against SARS-CoV-2. Front Plant Sci  2021,11,604663","journal-title":"Front Plant Sci"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.bbrc.2004.09.106","volume":"324","author":"He Y.","year":"2004","unstructured":"He Y.; Zhou Y.; Liu S.; Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine. Biochem Biophys Res Commun  2004,324(2),773-781","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"8683","DOI":"10.1039\/D0CC03263H","volume":"56","author":"Qi X.","year":"2020","unstructured":"Qi X.; Ke B.; Feng Q.; Construction and immunogenic studies of a mFc fusion receptor binding domain (RBD) of spike protein as a subunit vaccine against SARS-CoV-2 infection. Chem Commun  2020,56(61),8683-8686","journal-title":"Chem Commun"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"7205","DOI":"10.1016\/j.vaccine.2020.09.058","volume":"38","author":"Liu X.","year":"2020","unstructured":"Liu X.; Drelich A.; Li W.; Enhanced elicitation of potent neutralizing antibodies by the SARS-CoV-2 spike receptor binding domain Fc fusion protein in mice. Vaccine  2020,38(46),7205-7212","journal-title":"Vaccine"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1038\/s41423-021-00658-z","volume":"18","author":"Sun S.","year":"2021","unstructured":"Sun S.; He L.; Zhao Z.; Recombinant vaccine containing an RBD-Fc fusion induced protection against SARS-CoV-2 in nonhuman primates and mice. Cell Mol Immunol  2021,18(4),1070-1073","journal-title":"Cell Mol Immunol"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/s41392-022-01185-7","volume":"7","author":"Luo D.","year":"2022","unstructured":"Luo D.; Yang X.; Li T.; An updated RBD-Fc fusion vaccine booster increases neutralization of SARS-CoV-2 Omicron variants. Signal Transduct Target Ther  2022,7(1),327","journal-title":"Signal Transduct Target Ther"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"6601","DOI":"10.1016\/j.vaccine.2021.09.077","volume":"39","author":"Alleva D.G.","year":"2021","unstructured":"Alleva D.G.; Delpero A.R.; Scully M.M.; Development of an IgG-Fc fusion COVID-19 subunit vaccine, AKS-452. Vaccine  2021,39(45),6601-6613","journal-title":"Vaccine"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1016\/j.vaccine.2022.01.043","volume":"40","author":"Janssen Y.F.","year":"2022","unstructured":"Janssen Y.F.; Feitsma E.A.; Boersma H.H.; Phase I interim results of a phase I\/II study of the IgG-Fc fusion COVID-19 subunit vaccine, AKS-452. Vaccine  2022,40(9),1253-1260","journal-title":"Vaccine"}],"container-title":["Current Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1566524023666230410093243","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/215591\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1566524023666230410093243","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T06:10:04Z","timestamp":1713939004000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/215591\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1566524023666230410093243","relation":{},"ISSN":["1566-5240"],"issn-type":[{"value":"1566-5240","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-09-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-18","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-31","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}